Abstract: An immediate release drug containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.

Abstract: A system and method of removing material from pharmaceutical tablets, utilizing mechanical or laser energy and a conveyance, to produce a score or other defect in said tablet.

Abstract: A method is described for the treatment of hypotension, e.g., intra-dialytic hypotension, which is based on the administration to a patient, e.g. a dialysis patient during dialysis, of midodrine or a midodrine metabolite which will increase a lowered blood pressure in the patient or relieve a symptom caused by the dialysis procedure.

Abstract: A pharmaceutical tablet having two segments, one of which is a top segment and the other of which is a bottom segment, said tablet having at least one side wherein said tablet is provided with a separation mark or marks.

Abstract: Accurate means of dosing with a compressed, segmented pharmaceutical tablet, and tablettes formed from said tablets, is disclosed.

Abstract: A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments.

Abstract: Dosage forms containing torsemide as the active ingredient, preferably provided at a relatively low dose or strength, are disclosed. The dosage forms can, be formulated as a tablet having a novel scoring pattern enabling division of the tablet to provide unique doses and dosing regimens to be administered to a patient in need of treatment or prevention using torsemide.

Abstract: Deeply scored pharmaceutical tablets are disclosed, along with pharmaceutical tablets with a score in a segment that adjoins a segment lacking a pharmacologically effective dose of any drug.

Abstract: The invention provides novel scoring patterns for a wide variety of tablets that contain specific drugs or contain drugs in certain drug classes, and methods of treatment with layered tablets and fractional tablets derived from breaking said tablets.

Abstract: The invention provides novel scoring patterns for a wide variety of tablets that contain specific drugs or contain drugs in certain drug classes, preferably doxepin.

Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal crosssection, and measuring the length of a line that is at right angle to the shorter sides.

Abstract: The invention relates to low dose combinations of a thiazide diuretic and a mineralocorticoid inhibitor and methods for the treatment of hypertension and related disorders.

Abstract: The subject invention relates to a composition and method for treating a patient employing co-formulation or co-administration of a thiazolidinedione (TZD) and a diuretic.

Abstract: The subject invention provides compositions and methods of use of a single dosage form which includes therapeutic or subtherapeutic doses of a dihydropyridine calcium channel blocker (CCB), such as amlodipine, and a diuretic, preferably a thiazide-type diuretic, such as chlorthalidone.

Abstract: A method of treating patients suffering from renal failure and concomitant cardiovascular disease with a low dose of the cardiac glycoside known as digoxin, and novel dosage forms to accomplish the method and to perform other uses.

Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Abstract: The invention is directed to a method of treating systemic arterial hypertension which preferably uses enter administration of a once-daily dose of ethacrynic acid of less than 50 mg/day to a patient afflicted with arterial hypertension. Doses of less than 25 mg/day ethacrynic acid are also indicated for treating hypertension. The invention also includes novel dosage forms comprising from 2.0 to 20 mg of ethacrynic acid.

Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.